Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart

被引：27

作者：

Kinuya, S

Yokoyama, K

Izumo, M

Sorita, T

Obata, T

Mori, H

Shiba, K

Watanabe, N

Shuke, N

Michigishi, T

Tonami, N

机构：

[1] Kanazawa Univ, Grad Sch Med Sci, Dept Biotracer Med, Kanazawa, Ishikawa 9208640, Japan

[2] Japan Atom Energy Res Inst, Dept Res Reactor, Radioisotope Lab, Tokai, Ibaraki 31911, Japan

[3] Kanazawa Univ, Radioisotope Ctr, Kanazawa, Ishikawa 920, Japan

[4] Toyama Med & Pharmaceut Univ, Dept Radiol, Toyama, Japan

[5] Asahikawa Med Coll, Dept Radiol, Asahikawa, Hokkaido 078, Japan

来源：

CANCER LETTERS | 2005年 / 219卷 / 01期

基金：

日本学术振兴会;

关键词：

radioimmunotherapy; Re-186; peritoneal metastasis; colon cancer; locoregional administration;

D O I：

10.1016/j.canlet.2004.08.033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy of locoregional radioimmunotherapy (RIT) in treating peritoneal tumors of colon cancer of < 2 mm in diameter was examined at maximum tolerated doses, focusing the comparison between Re-186 and I-131 labeled to an anti-colorectal cancer IgG1. Estimated radiation doses to tumors were considerably higher with Re-186-RIT than with I-131-RIT. The advantage of Re-186-RIT decreased with decreasing tumor size, but Re-186-RIT delivered 1.6-times higher radiation to tumors of I mm. Consequently, Re-186-RIT attained better survival of mice than I-131-RIT or chemotherapy with 5-fluorouracil did. Therefore, locoregional Re-186-RIT may be an option in an adjuvant setting of colon cancer with high risk of peritoneal dissemination. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：41 / 48

页数：8

共 35 条

[1]

Borchardt PE, 1998, J NUCL MED, V39, P476

[2] Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis [J].

Borchardt, PE ;

Quadri, SM ;

Freedman, RS ;

Vriesendorp, HM .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (01) :53-64

[3]

BREITZ HB, 1993, J NUCL MED, V34, P908

[4]

BREITZ HB, 1995, CANCER RES, V55, pS5817

[5] Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration [J].

Buijs, WCAM ;

Tibben, JG ;

Boerman, OC ;

Molthoff, CFM ;

Massuger, LFAG ;

Koenders, EB ;

Schijf, CPT ;

Siegel, JA ;

Corstens, FHM .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (11) :1552-1561

[6]

Fujimori Kenji, 1994, Japanese Journal of Nuclear Medicine, V31, P241

[7] Status of radioimmunotherapy in the new millennium [J].

Imam, SK .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2001, 16 (03) :237-256

[8]

Juweid ME, 2002, J NUCL MED, V43, P1507

[9] Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy:: In vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice [J].

Kinuya, S ;

Yokoyama, K ;

Tega, H ;

Hiramatsu, T ;

Konishi, S ;

Yamamoto, W ;

Shuke, N ;

Aburano, T ;

Watanabe, N ;

Takayama, T ;

Michigishi, T ;

Tonami, N .

JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (08) :870-878

[10] Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts [J].